Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

NovaBay Pharmaceuticals to Hold 2019 Fourth Quarter and Full Year Conference Call on March 26, 2020


NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report 2019 fourth quarter and full year financial results after market close on Thursday, March 26, 2020 and will hold an investment community conference call that day.

DATE:

   

Thursday, March 26

TIME:

   

4:30 p.m. ET / 1:30 p.m. PT

DIAL IN:

   

800-608-8202 from within the U.S.

   

702-495-1913 from outside the U.S.

   

Enter conference identification number 5299253

The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time April 13, 2020, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 5299253. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, CELLERX® for the aesthetic dermatology market and NEUTROPHASE® for the wound care market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Socialize and Stay informed on NovaBay's progress:
Like us on
Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay's Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
www.Avenova.com


These press releases may also interest you

at 19:07
Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced it has entered into an agreement with the...

at 19:01
GPs say half of all appointments are for conditions that could have been managed by patients themselves Two thirds (67%) of GPs urge patients to take greater responsibility for their own health and relieve pressure on the NHS as restrictions continue...

at 19:00
Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announced today that Melissa Palmer, MD, an internationally renowned Hepatologist, will join...

at 12:00
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "As the resurgence of COVID-19 activity continues in Canada, we are tracking a range of epidemiological...

at 11:00
The most recent data on the evolution of COVID-19 in Québec show 1,395 new cases, bringing the total number of people infected to 141,038. The data also report 12 new deaths, for a total of 7 033. Among these 12 deaths, 4 have occurred in the last...

at 10:15
Ontario's doctors say that wearing a mask or other face covering is one of the easiest and most effective things everyone can do to stop the spread of COVID and save lives....



News published on 19 march 2020 at 06:55 and distributed by: